Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Boston Scientific Corporation

Related BSX
6 Reasons Why Needham Upgraded Boston Scientific
Benzinga's Top Upgrades, Downgrades For December 8, 2017
FDA OKs Boston Sci's deep brain stimulation system; shares ahead 2% premarket (Seeking Alpha)

In a report published Wednesday, Citigroup reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $7.30 to $8.20.

Citigroup noted, “BSX's shares have moved up significantly faster than we expected since last Thanksgiving, but we still see room for the stock on a fundamental basis as trends are improving and the peer group valuation has moved up. Plus, we still believe the call option on Durata being removed from the market is largely underappreciated.”

Boston Scientific Corporation closed on Tuesday at $7.10.

Latest Ratings for BSX

Dec 2017NeedhamUpgradesBuyStrong Buy
Nov 2017BTIG ResearchUpgradesNeutralBuy
Oct 2017BMO CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings


Related Articles (BSX)

View Comments and Join the Discussion!

Partner Center